Witteveen-Kolk Syndrome With Cleft Palate: A Case Report and Review of the Literature.

Witteveen-Kolk syndrome (WITKOS) is an exceptionally uncommon genetic and neurodevelopmental disorder, characterized by developmental delay, mild intellectual disability, and craniofacial dysmorphic features. Although cleft palate (CP) has rarely been reported in WITKOS, CP in this condition has not been assessed in detail. Here, we present a case of WITKOS with a CP.

Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study.

Background/objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy.

Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers.

The Serum Biomarkers in Ulcerative Colitis.

Objective: In this study, the aim was to evaluate the diagnostic effectiveness of more easily applicable and cost-effective serum biomarkers, such as neutrophil-to-lymphocyte ratio (NLR), platelet-tolymphocyte ratio (PLR), C-reactive protein (CRP) to albumin ratio (CAR), and CRP-to-lymphocyte ratio (CLR), instead of the endoscopic activity index (EAI) used to determine disease activation in ulcerative colitis (UC) patients.

Methods: Blood tests performed during the same period as colonoscopy were reviewed, and NLR, PLR, CAR, and CLR values were calculated. Based on the EAI score, patients with a score <4 were classified as having UC in remission, those with a score ≥4 as having active UC, and those with normal colonoscopy results as the control group.